Literature DB >> 24657328

Gradual versus abrupt quitting among French treatment-seeking smokers.

Monique Baha1, Anne-Laurence Le Faou2.   

Abstract

OBJECTIVE: This study examined the prevalence and predictors of gradual quitting among treatment-seeking smokers.
METHOD: This study examined quit attempts among 28,156 adult smokers who attended French smoking cessation services nationwide between 2007 and 2010. Predictors of gradual quitting were determined using multivariate regression models.
RESULTS: Only 4.4% quit gradually whereas 48.7% quit abruptly and 46.9% continued smoking. 34.1% of abrupt quitters and 31.9% of gradual quitters were abstinent at 1month post-quit (p=0.108). Gradual quitting was associated with: older age, heavy smoking at baseline, no previous quit attempts, low self-efficacy, baseline intake of anxiolytics, symptoms of depression and history of depressive episodes. Gradual quitters had a similar anxio-depressive profile than continued smokers but were more educated and more likely to have reported previous quit attempts. Prescription of oral nicotine replacement therapy (NRT) only as opposed to combination NRT doubled the odds of gradual quitting. Likelihood of gradual quitting compared with continued smoking improved with the number of follow-up visits.
CONCLUSION: Our findings suggest that hard-to-treat smokers may be more likely to quit gradually than abruptly. However, intense follow-up with adapted treatment appears to be crucial to achieve cessation gradually in French smoking cessation services.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abrupt quitting; Gradual quitting; Nicotine replacement therapy; Quit attempt; Smoking cessation; Varenicline

Mesh:

Substances:

Year:  2014        PMID: 24657328     DOI: 10.1016/j.ypmed.2014.03.014

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  1 in total

Review 1.  PURLs: "Cold turkey" works best for smoking cessation.

Authors:  Dustin K Smith; Deborah E Miller; Anne Mounsey
Journal:  J Fam Pract       Date:  2017-03       Impact factor: 0.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.